Given the ability of the herpes simplex virus to persist for a long time, leading to a decrease in the specific immune response, the treatment of cancer patients with concomitant herpesvirus infection (HVI) is a difficult task. In the 1980s, progress was made in the study of HVI related to the development of the first drug from the group of acyclic nucleosides. Usually, the treatment of HVI includes antiviral agents, analgesics, antipyretics, local drugs with antiviral components and anesthetics. However, well-known treatment for the disease does not provide complete elimination of the virus, and often after drug withdrawal, the symptoms occur, which causes problems in providing the medical care. Thus, the search for new ways to treat HVI, including in patients with a cancer, is relevant and necessary. The article describes the method for treating patients with HVI using in vitro activated autologous lymphocytes. Six clinical cases of successful treatment of genital herpes infection in patients were considered. Two patients had cancer, in the first case – cervical cancer, in the second – anal cancer. The conducted study allows to conclude that the uing of the method of adoptive immunotherapy for the treatment of patients with HVI improves the quality of life of the patient, induces the high immune response, which manifests itself in the duration of the relapse-free period from 8 to 45 months. © 2023, Dynasty Publishing House. All rights reserved.